These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1827305)

  • 1. Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy.
    van der Burg ME; Hoff AM; van Lent M; Rodenburg CJ; van Putten WL; Stoter G
    Eur J Cancer; 1991; 27(3):248-50. PubMed ID: 1827305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
    Hannigan EV; Green S; Alberts DS; O'Toole R; Surwit E
    Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
    Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
    J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Lund B; Hansen OP; Hansen HH; Hansen M
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose platinum chemotherapy in advanced ovarian cancer: a phase II study.
    Bertelsen K; Bastholt L
    Gynecol Oncol; 1992 Jan; 44(1):79-82. PubMed ID: 1730430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regimens with intraperitoneal cisplatin plus intravenuous cyclophosphamide and intraperitoneal carboplatin plus intravenuous cyclophosphamide are equally effective in second line intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T; Klasa-Mazurkiewicz D; Sznurkowski J; Emerich J
    Adv Med Sci; 2012 Jun; 57(1):46-50. PubMed ID: 22430042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study.
    Lancet; 1998 Nov; 352(9140):1571-6. PubMed ID: 9843101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer.
    Teeling M; Hayes Y; Fitzmaurice B; McGing P; Carney DN
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):102-6. PubMed ID: 1411620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.
    Edmonson JH; McCormack GM; Wieand HS; Kugler JW; Krook JE; Stanhope CR; Everson LK; Laurie JA; Ebbert LP; Malkasian GD
    J Natl Cancer Inst; 1989 Oct; 81(19):1500-4. PubMed ID: 2674460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
    International Collaborative Ovarian Neoplasm Group
    Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer.
    Gershenson DM; Morris M; Burke TW; Levenback C; Kavanagh JJ; Fromm GL; Silva EG; Warner D; Wharton JT
    Gynecol Oncol; 1995 Sep; 58(3):349-55. PubMed ID: 7672700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute.
    ten Bokkel Huinink WW; Dalesio O; Rodenhuis S; Dubbelman R; Hilton A; Franklin H; Koier I; van Tinteren H; van der Burg ME; van Oosterom AT
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):99-101. PubMed ID: 1411634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer.
    Marth C; Tropé C; Vergote IB; Kristensen GB
    Eur J Cancer; 1998 Jul; 34(8):1175-80. PubMed ID: 9849475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
    Swenerton K; Jeffrey J; Stuart G; Roy M; Krepart G; Carmichael J; Drouin P; Stanimir R; O'Connell G; MacLean G
    J Clin Oncol; 1992 May; 10(5):718-26. PubMed ID: 1569444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen.
    Bolis G; Scarfone G; Luchini L; Ferraris C; Zanaboni F; Presti M; Giardina G; Villa A; Parazzini F
    Eur J Cancer; 1994; 30A(12):1764-8. PubMed ID: 7880602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.